Here is an interesting note from M. Thabet: “Could you please forward the brand name and prescribing information for the new Russian version of recombinant factor VIIa (rFVIIa) similar to NovoSeven?”
Thank you for your question. NovoSeven goes off-patent in the United States in 2011, and Novo Nordisk is developing both a fast-acting analogue and a prolonged half-life PEGylated analogue, but I can find no record of a new Russian rFVIIa. Perhaps another participant can comment.
Dr. Moshe Baru, Omri Laboratories, Rehovot Israel reports work on a PEGylated form of rFVIIa, attempting to prolong its plasma half-life, however I see no evidence this has reached clinical trials. See Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008;14:476-483.